201 related articles for article (PubMed ID: 31298706)
1. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.
Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E
J Clin Endocrinol Metab; 2019 Dec; 104(12):5843-5852. PubMed ID: 31298706
[TBL] [Abstract][Full Text] [Related]
2.
Shah R; Sehemby M; Garg R; Purandare N; Hira P; Mahajan A; Lele V; Malhotra G; Verma P; Rojekar A; Dalvi A; Uchino S; Rastogi S; Lila A; Patil V; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2022 Feb; 96(2):190-199. PubMed ID: 34498757
[TBL] [Abstract][Full Text] [Related]
3. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
Michalski K; Laubner K; Stoykow C; Omrane MA; Maecke HR; Seufert J; Goetz C; Meyer PT; Ruf J
Clin Nucl Med; 2020 Jul; 45(7):519-524. PubMed ID: 32453080
[TBL] [Abstract][Full Text] [Related]
4. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
5. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia.
Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK
Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTATATE PET/CT imaging for insulinoma in MEN1 patient with endogenous hyperinsulinemic hypoglycemia: A case report.
Liu Y; Zhao X; Zhang J; Wang J; Zhang Z; Dai M; Wang N; Jing F; Wang T; Tian W
Medicine (Baltimore); 2022 Aug; 101(34):e30252. PubMed ID: 36042606
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.
Garg R; Shah R; Tiwari A; Purandare N; Lele VR; Malhotra G; Verma P; Gosavi V; Dalvi A; Kumar Jaiswal S; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2020 Dec; 93(6):678-686. PubMed ID: 32716527
[TBL] [Abstract][Full Text] [Related]
9. Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.
Antwi K; Nicolas G; Fani M; Christ E; Wild D
Clin Nucl Med; 2019 May; 44(5):e347-e348. PubMed ID: 30889001
[TBL] [Abstract][Full Text] [Related]
10. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
11. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
Sood A; Basher RK; Kang M; Shukla J; Behera A; Walia R; Nada R; Mittal BR; Bhattacharya A
Clin Nucl Med; 2019 Jul; 44(7):e428-e430. PubMed ID: 31107750
[TBL] [Abstract][Full Text] [Related]
13. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
15. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
16. Utility of
Kalff V; Iravani A; Akhurst T; Pattison DA; Eu P; Hofman MS; Hicks RJ
Intern Med J; 2021 Oct; 51(10):1657-1664. PubMed ID: 33314504
[TBL] [Abstract][Full Text] [Related]
17.
Tuzcu SA; Pekkolay Z; Kılınç F; Tuzcu AK
J Nucl Med Technol; 2017 Sep; 45(3):198-200. PubMed ID: 28798227
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.
Shah R; Garg R; Majmundar M; Purandare N; Malhotra G; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2021 Aug; 95(2):354-364. PubMed ID: 33386617
[TBL] [Abstract][Full Text] [Related]
19.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]